Nong Xu

机构：Zhejiang Chinese Medical University, Nanjing Tech University, University of Electronic Science and Technology of China, Hefei University, NAURA (China), First Affiliated Hospital Zhejiang University, Zhejiang University · ORCID：0000-0001-5774-7832

发表论文 182 篇 · 总被引 7856 次 · h-index 30

代表论文

• First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial (2025 · Nature Medicine · 被引 89)
• The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib study (2024 · Journal of Hematology & Oncology · 被引 19)
• Dual inhibition of LAG-3 and PD-1 with IBI110 and sintilimab in advanced solid tumors: the first-in-human phase Ia/Ib study (2024 · Journal of Hematology & Oncology · 被引 14)
• Blood Biomarker‐Based Predictive Indicator for Liver Metastasis in Alpha‐Fetoprotein‐Producing Gastric Cancer and Multi‐Omics Tumor Microenvironment Insights (2025 · Advanced Science · 被引 5)
• Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p) (2025 · European Journal of Cancer · 被引 4)
• Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial (2025 · Nature Medicine · 被引 2)